ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation

Cancer Biology and Therapy

Volumn 8, Issue 11, 2009, Pages 1045-1054

  Zheng, Xuguang ^a   Jiang, Feng ^a   Katakowski, Mark ^a   Zheng, Gang Zhang ^a   Lu, Qing E ^a   Chopp, Michael ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

ADAM17; Angiogenesis; Breast cancer; EGFR PI3K AKT; Invasion; Proliferation; TACE

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BROXURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIGEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SULFORHODAMINE B; TETRAZOLIUM BLUE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL INVASION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PLASMID; WESTERN BLOTTING;

ADAM PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 67649095267     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.11.8539     Document Type: Article

References (35)

1. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008.
2. Black RA. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002; 34:1-5.
3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-33.
4. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998; 273:27765-7.
5. Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 2005; 93:1267-76.
6. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181:1205-10.
7. Mullberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155:5198-205.
8. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733-6.
9. Bennett TA, Lynam EB, Sklar LA, Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J Immunol 1996; 156:3093-7.
10. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6:32-43.
11. Katakowski M, Chen J, Zhang ZG, Santra M, Wang Y, Chopp M. Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor-alpha-converting enzyme protease activity. J Cereb Blood Flow Metab 2007; 27:669-78.
12. Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G. Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie 2002; 48:500-9.
13. Zheng X, Jiang F, Katakowski M, Kalkanis SN, Hong X, Zhang X, et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 2007; 98:674-84.
14. McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 2008; 19:1075-81.
15. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284:2-13.
16. Sternlicht MD, Sunnarborg SW. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia 2008; 13:181-94.
17. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003; 74:342-52.
18. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2 and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 279:45643-51.
19. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 2000; 16:83-7.
20. He YY, Council SE, Feng L, Chignell CF. UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/Cyclin D1 pathways in keratinocytes. Cancer Res 2008; 68:3752-8.
21. Zheng X, Jiang F, Katakowski M, Zhang X, Jiang H, Zhang ZG, et al. Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett 2008; 265:177-87.
22. Ding X, Yang LY, Huang GW, Wang W, Lu WQ. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 2004; 10:2735-9.
23. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309:418-25.
24. Kenny PA. Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 2007; 35:665-8.
25. Kenny PA. TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation 2007; 75:800-8.
26. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-43.
27. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-65.
28. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164:769-79.
29. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13:2905-27.
30. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, et al. Mutant epidermal growth factor receptor upregulates molecular effectors of tumor invasion. Cancer Res 2002; 62:3335-9.
31. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008; 1784:150-8.
32. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18.
33. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol 2006; 209:56-66.
34. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97:1749-53.
35. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007; 117:337-45.